Aquestive Therapeutics, Inc.

NasdaqGM:AQST Stock Report

Market Cap: US$305.9m

Aquestive Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Dan Barber

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage24.0%
CEO tenure2yrs
CEO ownership0.9%
Management average tenure2yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Aquestive Therapeutics: A First Take

Aug 29

Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics

May 26

CEO Compensation Analysis

How has Dan Barber's remuneration changed compared to Aquestive Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$899kUS$300k

-US$14m

Compensation vs Market: Dan's total compensation ($USD2.50M) is about average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Barber (47 yo)

2yrs

Tenure

US$2,496,141

Compensation

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Barber
CEO, President & Director2yrsUS$2.50m0.93%
$ 2.8m
A. Toth
Chief Financial Officer3.4yrsUS$1.12m0.27%
$ 834.3k
Lori Braender
Senior VP5.7yrsUS$1.19m0.34%
$ 1.1m
Cassie Jung
Senior Vice President of Operations1.5yrsno data0.26%
$ 780.5k
Alexander Schobel
Chief Innovation & Technology Officer9.4yrsUS$810.02k1.08%
$ 3.3m
Stephen Wargacki
Chief Science Officerno datano data0.27%
$ 833.2k
Peter Boyd
Senior Vice President of IT1.2yrsno data0.26%
$ 798.4k
Gary Slatko
Chief Medical Officerno datano datano data
Carl Kraus
Chief Medical Officerless than a yearno data0.29%
$ 882.0k
Robert Arnold
VP of Financeno datano datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Management: AQST's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Barber
CEO, President & Director2yrsUS$2.50m0.93%
$ 2.8m
Santo Costa
Independent Chairman of the Board8.4yrsUS$202.16k0.019%
$ 58.2k
Timothy Morris
Independent Director1.8yrsUS$145.23kno data
Gregory Brown
Independent Director17.2yrsUS$150.77k0.082%
$ 252.3k
Julie Krop
Independent Director3.3yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board20.3yrsUS$137.23k0.11%
$ 334.3k
Marco Taglietti
Independent Director3.3yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board1.7yrsno datano data
Ruchi Gupta
Member of Scientific Advisory Board1.7yrsno datano data
David Bernstein
Member of Scientific Advisory Board1.7yrsno datano data
David Fleischer
Member of Scientific Advisory Board1.7yrsno datano data
Matthew Greenhawt
Member of Scientific Advisory Board1.7yrsno datano data

1.9yrs

Average Tenure

62yo

Average Age

Experienced Board: AQST's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.